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Identity 
Other names: PYY4 




History: NPY, first discovered in 1982 from pig brain, 
has been characterized as one of the most highly 
conserved neuroendocrine peptides through-out 
evolution. Its name derives from the single-letter code 
(Y) for the amino acid (aa) tyrosine, since it contai s 
five tyrosine residues including an amidated C-terminal 
tyrosine residue. Moreover, there is 92% aa sequence 
identity for NPY between the cartilaginous fish, 
Torpedo marmorata, and mammals, which are 
separated by an evolutionary distance of more than 400 
million years. These evidences indicate that NPY 
presumably has a critical physiological function and 
that interindi-vidual variation at this locus is likely to 
be minimal. The NPY gene is about 8 kilobases (kb) in 
length with four small exons (each, <200 base pairs 
[bp]) separated by three introns of approximately 965, 
4300, and 2300 bp. 
Description 
NPY encompasses 7,669 bp of DNA on chromosome 7 
(7p15.1) between 24290334 and 24298002 from pter. 
Transcription 
The NPY RNA transcript contains 4 exons and it is 551
bp, in lenght. In details, Exon 1 (86 bp)  
contains the 5'-UTR, Exon 2 (188 bp) encodes the 
signal peptide and the main part of the mature NPY 
sequence, except the last base of arginine codon 35 a d 
the last tyrosine codon. Exon 3 (82 bp) contains the last 
base of the arginine codon, the last tyrosine codon from 
the mature peptide, the glycine amide donor site, th  
dibasic cleavage site, and the main portion of C-
terminal flanking peptide of NPY (CPON). Finally, 




The coding sequence (291 bp) of NPY gene synthetizes 
the pre-pro NPY (see diagram), a pre-cursor peptide of 
97 aa residues (size 10.8 kDa), which is cleaved after 
28-aa, resulting in the pro-NPY, a 69-aa peptide. Pro-
NPY undergoes clea-vage by the proconverting 
enzymes (PC)1/3 and/or PC2 at a single dibasic site 
(Lys38-Arg39), releasing a 30-aa carboxyl terminal 
peptide, the C-flanking peptide of NPY (CPON), with 
so far unknown function and NPY1-39, which is further 
processed by a carboxypeptidase-like enzyme. The 
resulting NPY1-37 is finally amidated at its C-terminal 
end by the peptidylglycine-amidating monooxygenase 
(PAM) in a process that removes an additional aa 
(glycine) and produces the mature and biologically 
active peptide NPY1-36. Moreover, NPY can be further 
process, by two enzymes, dipeptidyl peptidase IV 
(DPPIV) and aminopeptidase P, into NPY3-36 and 
NPY2-36, respectively. NPY exhibits a three-
dimensional structure called PP-fold, which is 
characterized by a harpin-like structure and by a tpe II 
beta-turn, connecting a polyproline-like type  






Atlas Genet Cytogenet Oncol Haematol. 2010; 14(4)  405 
 
A schematic drawing of 97 aa pre-pro NPY which is further process up to the release of the mature and biologically active peptide NPY1-
36 and the 30-aa CPON peptide. 
 
II helix (residues 14 to 30), thus leading to a close 
proximity of N- and C-terminal ends of the peptide. 
Expression 
The 36-aa NPY is one of the most abundant peptides 
expressed in numerous brain regions (i.e, 
hypothalamus, amygdala, hippocampus and cerebral 
cortex), as well as in the periphery (i.e, liver, heart, 
spleen, endothelial cells of blood vessels), showing 
both pre- and post-synaptic actions. However, the 
adrenal medulla is the primary source of circulating 
NPY. 
In details, in the brain, it is synthesized by neurons of 
the arcuate (ARC) nucleus and it is active on the 
paraventricular (PVN), on the dorsomedial (DMN) 
nucleus, and on the A1 and C1 areas of the median 
preoptic area. In particular, in human, high levels of 
NPY mRNA were found in the dentate gyrus, caudate 
nucleus and putamen. In cerebral cortex the amount f 
NPY-immunoreactivity (NPY-ir) is present at the 
highest concentration in the cingulated and temporal 
cortices and at the lowest in the occipital lobe. NPY-
labeled cells are also found in subcortical white matter, 
whereas this expression is negative in white matter 
areas away from the cortex. The striatum shows 
heterogeneous levels of NPY mRNA with a higher 
expression in the nucleus accumbens and the ventral 
region of the caudate. In general, NPY neurons also
coexpress various neurotransmitters. In fact, ARC NPY 
sub-population coexpresses the neuropeptide agouti-
related peptide (AgRP) and the amino acid gamma-
aminobutyric acid (GABA), whereas the brain stem 
subpopulation coexpresses the adrenergic trans-mitters, 
epinephrine and norepinephrine. 
In the periphery, NPY is expressed in the sympathetic 
nervous system, co-stored and co-released with 
norepinephrine, as well as in non-sympathetic neurons 
in several organs including gastrointestinal tract, 
salivary glands, thyroid gland, pancreas, urogenital 
system, Schwann cells and heart. NPY is also present 
in cholinergic and non-cholinergic neurons (both 
central and peripheral) with anti-depressant, anti-
convulsant and anti-nociceptive actions. In the 
mammalian intestine, NPY is present in both myenteric 
and submucous neurones that provide an extensive 
intrinsic innervation to smooth muscle layers and 
mucosal targets, respectively. NPY has been detected 
in glial cells and in olfactory Schwann cells, thereby 
potentially affording trophic support. NPY-ir appears 
mainly found in the renal tubules, whereas it seems 
absent in the glomerules. Interestingly, in infant colon, 
41% of submucous plexus (a  
combination of Henle's, intermediate and Meissner's 
plexi) cell bodies are NPY-positive and co-localised 
with nitric oxide synthase immuno-reactivity. 
Localisation 
Stored in cytoplasmatic secretory granules within te
cell body and peptidergic nerve terminals. It is secreted 
upon specific stimuli. 
Function 
NPY has been involved in the regulation of a wide 
range of physiological central effects like the contr l of 
appetite, body weight homeostasis, the modulation of 
reproductive processes, the regula-tion of growth 
hormone secretion. Moreover, it is involved in the 
anxyolytic effect and sedation, in the endogenous 
anticonvulsant activity, in the circadian rhythm 
regulation, in learning and memory, in analgesia and
hyperalgesia. 
1) Food Intake 
Being NPY a very potent stimulant of food ingestion, 
and mainly of carbohydrates, among these NPY-
mediated actions, the major one is its role in the control 
of appetite, body weight homeostasis, and obesity. All 
these functions are mediated in humans by different 
receptor subtypes, so-called Y receptors: Y1-R, Y2-R, 
Y4-R, Y5-R and y6-R (a pseudogene in primates, with 
no shown activity as yet), which all belong to the large 
family of Gi-protein coupled receptors. 
2) Cardiovascular function 
NPY has also been described to mediate peripheral 
effects including the regulation of the cardiova-scular 
system, vasoconstriction, the release of cate-
cholamines by the adrenal medulla and vascular 
motility. About 25% of patients with acute heart failure 
were found to display an increase in circulating NPY 
levels. NPY has been proposed to be an useful marker 
for estimating the condition of patients suffering from 
cardiac diseases. In fact, plasma NPY 
immunoreactivity appeared elevated in patients with 
acute myocardial ischemia and in those with congestive 
heart failure. Moreover, NPY appears to enhance 
diuresis and natriuresis through direct tubular effects 
independent of its hemody-namic properties. 
The vasopressive properties of NPY as well as its 
capacity to potentiate adrenergic responsiveness 
suggests that this peptide might be beneficial in the 
management of endotoxic shock. Indeed, in humans  
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experiencing sepsis and septic shock, plasma levels of 
NPY are significantly increased and NPY-mediated 
vasoconstriction was shown to be preserved during 
endotoxemia. 
3) Cancer 
Besides these physiological events, in the context of the 
biology of cancer progression, recent evidence has 
extended the oncological relevance of NPY to 
endocrine-related cancers (see below). 
Homology 
The alignment of mature tetrapod NPY sequences 
reveals constant positions (91% identity) and only 4 
positions are allowed to vary. In particular, amphi-
bians sequences display an Arg-Lys replacement at 
position 19, porcine and bovine a Lys-Met replace-
ment at position 17, ovine an Asp-Glu replacement at 
position 10, and chicken an Asn-Ser replacement at 
position 7. On the contrary, identical sequences of 
human mature NPY have been found in monkey, rat, 
rabbit, guinea pig, and alligator. 
Mutations 
Note 
So far, in the literature there are many evidence which 
connect NPY and NPY receptors to a condition or 
disease, like hyperlipidemia, enhanced rate of 
atherosclerosis, increased body mass index (BMI), 
higher birth weigh, as well as alcohol dependence, 
depression and schizophrenia. To date there are 
reported only two non-synonymous sequence variants 
in the signal sequence part of NPY gene (p.L7P; 7th aa 
of the preproNPY, leucine, is changed to proline; 
rs16139) and c.64C>A (p.L22M; 22nd aa of the 
preproNPY, leucine, is changed to methionine; rs5571). 
The single nucleotide polymorphism (SNP) L7P was 
originally discovered in 1998 in Finnish and Dutch 
populations. It varies from 6% to 15% in the Caucasian 
populations and it seems to be totally absent or 
extremely low in oriental populations. L7P substitution 
is located in the signal peptide part of preproNPY and it 




Endocrine-related cancers are malignancies depending 
at least in part upon the trophic effect of specific 
hormones, and include breast, ovarian and prostate 
cancers, and to endocrine (pituitary tumors, 
adrenocortical lesions) and neuroendocrine (pheo-






The involvement of NPY and NPY receptors (NPY-Rs) 
in the progression of endocrine-related cancers may be 
associated with: (a) expression of NPY-Rs in the 
context of the tumor, thus becoming a target of 
extratumorally secreted NPY proximal to the tumor. In 
this context, the presence of NPY-Rs may be targeted 
by specific drugs with either agonist or antagonist 
activity or by radiolabeled compounds (the universal 
ligand 125I-labeled PYY, the selective Y1-R 125I-labeled 
[Leu31, Pro34]-PYY and the selective Y2-R 
125I-labeled 
PYY3-36); (b) in situ production of NPY. Tumor-
produced NPY may act locally in a paracrine fashion 
and/or reach the bloodstream and generate systemic 
effects. The measurement of NPY plasma levels may 
have the value of a diagnostic marker; (c) a 
combination of expression of NPY-Rs and local 
production of NPY by the tumor. NPY effects may 
result in either promotion or suppression of cancer 
growth through paracrine mechanisms. 
NPY is then involved in specific steps of cancer 
progression, like cell proliferation, matrix invasion, 
metastatization, and angiogenesis. Proliferative or anti-
proliferative effects of NPY have been shown in 
different cell systems and appear mediated mainly 
through the Y1-R, which has been involved in the 
control of the proliferation of vascular smooth muscle 
and endothelial cells and injured glial cells. NPY has 
also been found to modulate the proliferation of hepatic 
stellate cells and neural crest-derived tumors. 
NPY significantly enhances also angiogenesis in 
various ex vivo and in vivo models of angiogenesis, 
such as aortic sprouting, Matrigel plug assay, and 
ischemic hind limb revascularization. NPY-driven 
angiogenesis has been proposed to be bimodal at least 
in vitro (at low and high concentration, 10-12 and 10-8 
M, respectively) and through oligomerization of Y1-, 
Y2-, and Y5-R. These data might explain the in vivo 
NPY-induced angio-genesis both in tissues that contain 
low NPY concentrations, such as the 
nonsympathetically innervated aorta or growing organs 
lacking a mature NPY system and in tissues containing 
high NPY concentrations, such as the heart, mature 
vessels or muscles during high sympathetic activity 
induced by stress, ischemia, or injury. Nevertheless, by 
using an in vitro assay to test the multistage process of 
metastasis (cell attachment to extra-cellular matrix 
(ECM), enzymatic degradation of ECM, and migration 
to fibronectin) it has been demonstrated that NPY 
affects tumor matrix invasion. In particular, it inh bits 
the invasion of murine Colon 26-L5 adenocarcinoma 
cells through a reconstituted basement membrane, 
whereas on both the DU145 and PC-3 human androgen 
independent prostate cancer cells it was not. In none of 
the tumor cell lines considered, as neither on LNCaP  
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human androgen dependent prostate cancer cells NPY 
enhanced the haptotactic migration. 
Atherosclerosis 
Note 
In 1998 it has been reported that the P7 allele (p.P7) in 
the NPY signalling peptide could be strongest genetic 
factor influencing serum cholesterol and low density 
lipo-protein (LDL) levels in obese subject. Two 
independent studies showed that: a) men with P7 
substitution had a four-year increase in the mean and 
maximal common carotid intima-media thickness 
(IMT), b) increased carotid IMT in type 2 diabetes 
patients, c) obese subject with BMI > 30 Kg/m2 had 
increased serum total cholesterol and LDL cholesterol. 
On the contrary, in 443 children with a family history 
of cardiovas-cular disease (CVD) the Leu7Pro 
polymorphism was not associated with serum lipid 
values after adjustment for body weight in boys or 
girls, but may be associated with dietary response to 
LDL-cholesterol concentration in overweight boys with 
a family history of early-onset CVD. 
Obesity 
Note 
Although the role of NPY in the regulation of human 
feeding is not fully clear and there are several negative 
studies, in 2005 a study conducted on Dutch population 
of non-obese subjects, highlighted that both men and 
women, carried the L7P substitution, had higher mean 
BMI values. On the other hand, one conflicting study 




The L7P polymorphism has been associated with onset 
of type 2 diabetes, impaired glucose tolerance and with 
a worse glycaemic balance in type 1 diabetic patients as 
measured by HbA1c levels. In addition, the preproNPY 
Pro7 carrier status, in middle-aged subjects, was a 
significant risk factor for type II diabetes and they were 
more insulin resistant and showed lower ghrelin levels 
compared to non-carriers. In general, healthy subjects 
with p.P7 allele have higher glucose, lower insulin and 
lower insulin/glucose ratio during rest, after meals, nd 
during exercise. 
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